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1. Introduction 
Diseases of poverty are those diseases identified as affecting the poorest and most 
disadvantaged populations in the world. Poverty is one of the main risk factors for the 
conditions, creating exposure to poor water and sanitation; poor nutrition, poor 
environmental conditions that favour the growth and spread of micro-organisms and vectors 
that cause and transmit disease; and lack of education and access to appropriate disease 
prevention, health promotion, treatment and rehabilitative services. Diseases of poverty 
include for instance, the neglected tropical (communicable) diseases (NTDs) which until 
relatively recently were considered low priority for both governments and pharmaceutical 
companies (1–4). Furthermore, diseases of poverty increasingly include the non-
communicable diseases (5–7); hypertension, cardiovascular diseases, diabetes and other 
metabolic diseases and cancers, previously considered diseases of affluence (8–11). While 
there is some variation in the specific drivers that cause and exacerbate the communicable 
and non-communicable diseases for the poor, invariably, the processes and context are 
similar, impeding choices for healthier lifestyles, access to and acceptability and affordability 
of regular and quality care for chronic conditions and strategies for prevention and health 
promotion. In turn, affliction with these diseases hinders economic opportunities and 
development and perpetuates poverty. The disease increases vulnerability and exposure to 
poverty by increasing household expenditure and decreasing household income. 
Through mechanisms provided by the Millennium Declaration and associated Millennium 
Development Goals, the World Economic Forum, the Global Fund, the Bill and Melinda Gates 
Foundation and the US President’s Emergency Fund for AIDS Relief, the global health 
community has highlighted the plight of the poor and vulnerable, and gained support to 
address the major diseases. There is more funding available in global health now than there 
has ever been before (12–14). Major drug companies have committed to free donation of 
particular pharmaceuticals in an effort to achieve elimination of a number of diseases (15). The 
more recent UN Summit on NCDs employed this global advocacy process to elicit support 
from the highest levels of government to address the growing burden of specific chronic 
diseases. Critically however, programmes that result from these global health campaigns have 
historically been characterised largely by disease focused, vertical interventions that treat 
communities as a collective, providing a large scale clinical intervention. Much less attention is 
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focused on the more persistent underlying contributors to diseases of poverty – poverty and 
its other contextual drivers that are intimately interlinked with the diseases and outcomes. 
In this discussion paper, we argue that despite the importance of these contextual drivers, 
they are largely neglected in the science and evidence that contributes to solutions for 
addressing diseases of poverty. We begin with the premise that there are fundamental 
differences in the ways that different disciplines conceptualise health, illness and disease. 
From a biomedical and clinical sciences perspective, diseases of poverty represent ‘slugs, 
bugs and drugs’ and present an ideal opportunity for technical fixes. There is robust 
evidence on the efficacy of these fixes and a strategy based on this evidence presents good 
value for money(16–20). From the perspective of the social sciences however, there is less of 
a separation between the person, the human condition, the environment and the disease 
process. The interest, from a social science perspective is primarily in the social, cultural, 
environmental and economic drivers of poverty and disadvantage, societal norms that 
mitigate marginalisation and the ecological factors that determine who becomes ill, what 
they do about it, and the outcomes of the illness. This would therefore also encompass the 
contextual factors that would enhance or hinder the delivery of a given biomedical strategy 
that involves populations. While robust and theoretically grounded, evidence from social 
science research and solutions that arise from that research may not necessarily present the 
kinds of context free, quantifiable, linear solutions that are frequently desired under 
biomedical research models. Similarly, under social science models, a solution that removes 
proximal causes of suffering without addressing the more distal and complex contextual 
factors that continue to put populations at risk, may not appear to be a desirable end point 
for a strategy. In this paper therefore we explore: 
1. The contextual factors the define diseases of poverty; 
2. The challenges in conceptualising and operationalizing these factors for the purposes of 
generating evidence; 
3. The barriers to the translation of social science generated evidence in global public 
health; and  
4. Some solutions to rebalancing the scientific approaches to neglected.  
To address these questions, this report consists of a critical review of the diseases of poverty 
with a focus on the social, cultural, environmental and other contextual factors that affect 
risk, exposure, treatment and sequelae. In this context, diseases of poverty refer to the 
neglected diseases defined as those diseases which (i) have a disproportionate effect on the 
most disadvantaged sections of the community (the poor and marginalised); and (ii) lack 
investment in research and development for solutions that are explicitly accessible to the 
disadvantaged. We then provide a critical analysis of the sciences required to explore the 
complex nature of neglect in diseases of poverty and offer some suggestions for a broader 
approach to achieving long term solutions.  
2. The context of diseases of poverty 
Most of the conditions identified as diseases of poverty are treatable with currently available 
drugs. That notwithstanding, prevalence of these conditions remains high and the 
conditions persist (21). The neglected tropical diseases campaign for instance has 
relentlessly highlighted the plight of the populations affected by the range of target diseases. 
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A great deal has been made of stigmatization, disfigurement, persistent poverty, poor 
maternal and child health outcomes, poor health and education of children caused by 
infectious diseases (4,22–24). The choice of the word “neglect” is pointed and loaded, forcing 
us to reflect on our social obligations. Inherent in this campaign strategy is an appeal for the 
recognition of human suffering and the need for social justice (25).  
These issues have been raised time and again by researchers working across the areas of 
health and human rights, the social determinants of health (26) anthropology and sociology 
(27–31) to mention a few. At the very least increasing standards of living, provision of the 
basic human rights of food, shelter, and clothing are definitive interventions towards the 
elimination of diseases of poverty. The body of evidence that supports the need for 
structural intervention is significant (32) and is obvious in the lack of these diseases in 
communities with an even marginally higher socio-economic status than “the bottom 
billion” (33). Tackling structural problems is harder because the interventions required are 
more complex; some have suggested too complex to consider (34). However not intervening 
at these levels increases the futility of current efforts. The re-emergence of diseases that were 
supposed to have been eradicated 40 years ago (35) is a case in point.  
Other vulnerabilities highlighted in diseases of poverty include stigmatisation, social 
isolation, and disfigurement. These are vulnerabilities that result from social and cultural 
norms of what is considered normal and who is an acceptable member of the community 
(28,36,37). The effects of these on health relate to values that are less tangible than disease; 
equity, opportunity, access - and require intervention at different levels. 
The basic concern here is not new and to a significant degree, revisits the major, largely 
unresolved debates that raged almost 40 years ago between proponents and opponents of 
Primary Health Care (PHC) (38–40). The critical question is this: does one partition out 
individual, proximal, biological causes (i.e., the disease) and address them as independent 
context free problems, or is there a need for a different approach which attempts to address 
the multiple distal and proximal causes within the context in which they occur? The primary 
health care debates addressed this question in favour of a disease specific approach with the 
introduction of Selective Primary Health Care programmes (41), vertical programmes. This 
establishes the putative ‘pro-poor’ credentials of diseases of poverty, despite the focus on 
identifying unabashed medical and technological fixes – the “magical bullet” to combat 
disease (38).  
The contribution of the biomedical technologies cannot be underestimated. However, unless 
there are also significant interventions to address health and poverty, and the myriad 
marginalising factors in the social, cultural, economic, political and physical environments 
in which affected populations live, there will continue to be neglected people. Even in the 
research into the NTDs there is a distinct and patent disinterest in the social and contextual 
(42). Vaccines and drugs do not cure neglect or poverty and are not sufficient to rescue the 
neglected bottom billion from poverty (18). 
3. The Implementation gap
1
 
Even if it is decided that it would be safe to focus on the health side of the agenda rather 
than the poverty side, social and environmental (i.e., contextual) concerns cannot be 
                                                 
1 This section draw significantly on earlier work of the authors and re-presents a number of the ideas 
without repeated citation, but also extends on some of those ideas(43). 
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avoided. An almost exclusive focus on the biomedical overestimates the value of the current 
science, leaving unresolved issues with implementation; that is, embedding a putatively 
effective intervention in a community. It is, after all, not enough to have the perfect cure if 
no one in need is able to receive it. Whether an intervention to be implemented in neglected 
populations has the same benefit in that population as it does in another population is an 
empirical question. 
The randomised control trial (RCT) is widely regarded as the “gold standard” form of 
scientific evidence for establishing the effectiveness of a treatment (i.e., the cause effect 
relationship between treatment and cure), with decreasing levels of evidence treated with 
increasing levels suspicion. The problem with the RCT (and the levels of evidence) is that, in 
a general sense, and contrary to the expectations of many researchers, an RCT does not 
show the effectiveness of a treatment. It shows the effectiveness of a treatment in a 
particular context. Conducting multi-site RCTs, or conducting meta-analyses of multiple 
RCTs supports the generality of the finding. However, the conclusions about effectiveness 
can never be made without acknowledging the very controlled nature of experimental 
studies on which the conclusions about effectiveness are based; and by extension, the 
limitations imposed on generalising the results into less controlled, more realistic, contexts. 
The intention to treat (ITT) analysis of RCTs is a partial acknowledgement of the problems of 
context. In the simplest kind of RCT, patients are randomly allocated to a treatment or a 
control (non-treatment / “usual treatment”) group. Imagine that some people who were 
allocated to the treatment group ended up receiving no treatment – just like the control group. 
Under the ITT analysis, one analyses the results of the intervention as if all the people allocated 
to the treatment group, even those who did not receive treatment, did end up receiving 
treatment. This can seem somewhat counter-intuitive. Why would one analyse data counter to 
the reality of what happened? The analysis, however, establishes the effectiveness of a policy, 
i.e., an intention to treat patients in a particular way. The biological efficacy of the treatment 
should have already been established in early stage trials, and not be in doubt. The ITT 
analysis established the effectiveness of a treatment policy in a particular clinical setting.2 
The use of community-based trials, and 'less rigorous' forms of effectiveness study try to 
capture the likely context in which an intervention might actually be employed; and to some 
degree they support the generalisation of the findings. A caveat, however, always remains, 
because study sites are inevitably different from sites that do not fall under the scrutiny of 
researchers. The context of the research study is not the context in which most lives are 
lived. The generalisation of the conclusions from the research study site to the populations 
that do not live under those conditions goes beyond the science. 
The philosopher of science Nancy Cartwright raised points relevant to this argument in other 
branches of science. The issue is about what one knows in a general sense from doing scientific 
research. One of her points was that what one knows, relates to the context in which the 
research was conducted. Two illustrative examples of hers relate to the electronic transistor and 
to a leaf blowing in an alley. Consider the first example of the electronic transistor; a device used 
to regulate the flow of electricity. The basis of the transistor is grounded in quantum physics – a 
                                                 
2 Interestingly, DDR recently read a description of statistical techniques to avoid the ITT analysis, so 
that the “true” effect of the intervention could be estimated. This presupposes that the idea of a true 
effect devoid of a context in which a treatment is applied makes any sense – which seems very doubtful.  
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theory that is free of contextual considerations. This means that a transistor works the same in 
New York, Bogotá, and Ouagadougou. When you start your laptop computer, which has 
millions of transistors, you do not first have to find out where to make contextual adjustments 
to the transistors. Superficially the science under-pinning the transistor looks to provide the 
very kinds of context-free insight that real science is all about.  
On reflection the context-free nature of the findings are superficial. It is not the case that the 
transistor works in all contexts; rather, industrial manufacturing processes have been 
developed which make sure that the context within the transistors' housings remain the same 
without regard to where the transistors are. In effect, manufacturers have learned to create 
miniature, identical, controlled environments, with a fixed context of operation that conforms 
to an idealised model. The quantum effects work reliably and consistently within the bounds 
of the miniature environment, but without the same certainty outside that environment. 
The second example is of a leaf. Science and engineering has provided significant insights 
into aerodynamics. We have instrumentally valuable theories that predict airflow and lift. 
Empirical work in wind tunnels, computer simulation efforts and theoretical advances allow 
for very precise predictions to be made about how aircraft will behave under a range of 
plausible environmental conditions. Predicting the path, however, that a leaf will follow 
when blown down an alley is beyond us. The idealised understanding that we have of 
aerodynamics allows us to frame and control the context of the science that is done. Aircraft 
wings are crafted so that they maximise our predictive capacity, and conform to our 
understandings of the laws of aerodynamics. When we cannot control the context of the 
science, however, what we actually know becomes far less impressive. 
These observations are not pedantry, and they do not belittle the science that allows us to fly 
aircraft and build computers. What they do suggest, however, is that our science works 
because we know and understand the context in which it is applied. With a change in 
context, the success of the science is less certain. When developing health interventions, we 
do not have the luxury of constructing the context to suit the kinds of interventions or 
designing the intervention to work in a single context. Rather, we need to engage in the type 
of science that embraces interventions that are contextually appropriate.  
At a recent scientific meeting on community directed ivermectin distribution program for 
the control of Onchocerciasis, a report was presented from Nigeria where the intervention 
was not achieving the results anticipated given known effectiveness and the reported high 
coverage of ivermectin. When the gap between coverage and results was investigated, the 
evaluation team found that the villagers were receiving the ivermectin; however, instead of 
taking the tablets themselves, they were distributing them among their cattle. The villagers 
had decided that the economic benefit of a healthy herd far out-weighted the health loss 
they faced by failing to treat their personal affliction with onchocerciasis. 
The science had shown that ivermectin was a clinically effective approach to onchocerciasis 
control in one context. Community-based trials confirmed the effectiveness after scaling up 
the intervention in another context (44); and the economic analysis showed that it was cost-
effective (45,46). This was the 'truth' as revealed by the science of fixed contexts. The reality, 
however, was that the effectiveness of the intervention depended on a range of contextual 
factors – such as competing economic incentives. Having located the research in fixed (or 
well regulated) contexts, the likely variability of outcome that occurs in the wilds of real life, 
did not enter into any decisions about effectiveness. 
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There are two important corollaries to this. The first: imagine two interventions both of 
which are significantly more effective than no treatment. Furthermore, in clinical trials 
researchers have established that intervention A is significantly more effective than 
intervention B (i.e., 0A B> > ). When the context changes from the controlled research 
environment to point of implementation, the apparent magnitude of the effect of the 
interventions can reverse, with intervention B having a greater effect than intervention A 
(i.e., 0B A> >  or 0B A> = ). This will occur if, at the stage of implementation, the more 
effective A cannot be embedded in the community.  
The second corollary, which is an extension of the first, is that interventions that seem to be 
cost-ineffective in one context maybe the cost-effective interventions in another context, and 
the cost-effective intervention in another context will be the cost-ineffective intervention in 
this context. Continuing to use interventions A and B, following the effectiveness studies, 
the economic analysis established that A is more cost-effective than B. However, on 
implementation, when A fails to achieve any community up-take, B becomes the more cost-
effective of the interventions. The implications of this are hard to under-estimate.  
Decision making based on effectiveness and cost-effectiveness, which is a rational approach 
to the optimal allocation of scarce resources, may fail dramatically if the information on 
which the decision is based comes from the partial science of fixed contexts. 
As Allotey et al. observed (p.3), effectiveness is regarded as the appropriate end point for 
most intervention research. But knowing that a treatment is effective in routine clinical care 
is not enough, particularly in resource poor settings (i.e., the settings of the neglected). The 
goal must be the sustainable adoption of the intervention by the health systems and the 
target population, and not simply the establishment of effectiveness in a monitored clinical 
population. In other words, an intervention must become embedded; firmly integrated as 
part of the health system and the health culture of the disease endemic setting. It must be 
available, acceptable, accessible and affordable to those who need it; used appropriately, 
and become a part of the disease prevention, treatment seeking culture. 
Biomedical research is neither intended to address nor capable of addressing questions 
about implementation. Thus, not only is the value of the biomedical research limited by our 
lack of research on the contextual effects associated with implementation, it is also outside 
the expertise of those scientists to address the issues. 
4. The science of the neglected 
To this point we have argued that the approach to the neglected diseases has leveraged the 
idea of the vulnerable and neglected population to advance an argument for providing 
additional resources to the biomedical scientists so that they can develop cures for neglected 
diseases – “vaccines against poverty”. We then discuss the evidence about social 
vulnerability to disease, and the possibility of social interventions that address more distal 
causes of disease – intervening before the biomedical concerns arise. Finally we argued that 
the focus on proximal interventions is based on a flawed notion of the under-lying science 
and the generality of that science. In effect we argue for the development of contextually 
relevant science capable of accounting for social and environmental factors affecting the 
implementation of interventions. 
What is missing from our discussion is (i) the research that supports the implementation of 
proximal cures, and (ii) the research that supports distal interventions that change the social 
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vulnerability of neglected populations to disease. The obvious place to look for this research 
is in the social sciences literature, or the intersection between the clinical, biomedical, and 
social sciences literature. 
In a bibliometric analysis of four diseases of poverty (chikungunya, dengue, leishmaniasis, 
and onchocerciasis) we found that social sciences contribute to less than 2% of the published 
research (42). That was a generous counting of the social sciences contribution. The research 
that was funded was generally insipid, because it was there to act as a hand-maiden for 
biomedical research, never intended to support a research agenda of implementation or 
distal intervention. And the lack of a social sciences research agenda has a negative impact 
on the value of the biomedical research that is conducted, and limits our options for 
intervention to proximal cures. 
To say that the social sciences have been totally overlooked in the global health efforts would 
however be inaccurate. The value of the social sciences up until now, however, is qualified. In 
the area of NTDs, evidence from anthropological studies on stigmatization, the lived 
experiences of patients disfigured by diseases such as leprosy, yaws, onchocerciasis and 
filariasis, and the effects of these on health seeking, access to and quality of care, have been used 
particularly to support advocacy (4,18,28,53,24,54,55). The research that explores the reasons for 
the failures of programmes for instance is not insubstantial. Anthropological research has 
provided data on the importance of cultural and social constructions of illness and disease. We 
have some understanding of the different levels of practitioners, how and why they might be 
consulted and their role (or lack thereof) within a formal health system. There is evidence from 
the social sciences of the complexities and pathways to health seeking, the economic and social 
drivers, the effects of gender and other social determinants. Health economics has shed light on 
willingness of patients or clients to pay for different types of health services, interventions and 
pharmaceuticals; and the local market forces that hinder or enable distribution of and access to 
health services and pharmaceuticals. Health services and health systems research provides 
rigorous data on the socio-economic and political context in which local, national and global 
health policy supports (or otherwise) disease control programs.  
In broad terms however, social science research in this area has to date focused largely on 
the evaluation of the implementation process and on factors that will enhance community 
participation in community based programs (56). Both the process and the outcome 
indicators therefore relate to the administration of treatment and where appropriate, a short 
term reduction in NCDs. In other words these approaches to ‘deploying’ the social sciences 
are rather utilitarian and often tokenistic (43). The consequences to this are the often 
questionable quality of the social science evidence generated. Implementation research for 
instance, if well designed and implemented has the potential to contribute significantly to 
disease control efforts – however it is an area of research that is poorly funded (43) The 
problem arises often because social scientists are invited onto teams to undertake specific 
research projects rather than being a conceptual part of the planning of the intervention (27) 
To obtain the higher objective of improving the health and reducing vulnerabilities, it is 
important for researchers, policy makers and funding agencies to broaden the perspective 
on the range of research that is needed to address neglected diseases of neglected 
populations, and to rethink the types of integrated interventions and the nature of evidence 
to show effectiveness. There is a need to refocus on the health of neglected populations - 
health as an enabling process (38) - and not merely removing disease.  
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Critical opportunities are missed through the lack of integration of data from the social 
science disciplines. Health and illness are social constructs and as such, the disciplines and 
theories that help us to make sense of these issues should be as much a part of the agenda as 
pharmaceutical developments. It is tragic, for instance that so much is made of the suffering 
of patients of neglected tropical diseases, but there is little if any evidence in the funded 
programmes that addresses how families and communities affected by these diseases could 
be supported to deal with the social and economic sequelae. Studies of outbreaks of 
infectious diseases in South East Asia also highlight the almost exclusive disease focus of 
public health interventions and the total neglect of the mental health and social and economic 
consequences of these interventions (described as social chaos) on the populations affected 
(57). To address these issues would require a more complex understanding of the community 
and its dynamics and the broader political context in which the affected populations live. 
Studies in gender for instance have produced frameworks that facilitate the integration of 
gender across programmes. Similar approaches have been suggested for use with the social 
sciences (27,43,57,58) 
5. Alternative models 
There are essentially two issues that are conflated in the advocacy and the current approach 
to diseases of poverty. The first is the focus on neglect and vulnerabilities – as highlighted 
above, a significantly complex issue which we, as global health professionals, have an 
obligation to address (47). These issues cannot however, be fully addressed by vertical 
programmes. The second is the specific issue of disease which forms an important part of 
the factors which may be the cause of, but also exacerbate and sustain poverty and 
vulnerability. This issue is the focus of vertical programmes (41). Interventions to address 
these two issues should clearly not be mutually exclusive, but often are.  
The question of which general approach is better does depend on the expected outcomes but 
may of course be empirical. Assuming that the expected goal, as most global health 
programs stipulate, is the improvement of the health of populations, how would a poverty 
reduction, empowerment, equity based development programme fare against a preventive 
chemotherapy programme for instance, or one that combined approaches. Studies that test 
this empirically are rarely designed, in part because the different interventions seek different 
outcomes. Vertical programmes measure success in terms of reductions in the occurrence of 
specific diseases. Contextually based, comprehensive programmes count some broader 
measure of well-being as the desirable outcome. However it is difficult to imagine that there 
would be no value added to ensuring that the pieces lock together seamlessly. Programmes 
that privilege longer term improvements in the living conditions over merely achieving 
significant coverage of mass drug administration have shown a greater impact in rescuing 
communities and tackling concerns about neglected diseases and neglected populations 
(48). These tend to be smaller programmes, with significant input from communities and do 
not operate under the pressures of reporting to funders. Furthermore, when the outcomes of 
such programmes are published, the robustness of the ‘evidence’ is often questioned 
because they were not designed as ‘empirical’ studies (4,49–51). 
There are data that could arguably have the potential to provide a proxy indication of how 
the different approaches measure up. We know for instance that significant funds have been 
invested into global public health most of which have gone into vertical programmes 
dealing with the big three and more recently, the neglected tropical diseases (13,52). Data 
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are also available on investments into other programmes designed to meet the other 
millennium development goals, which also address the vulnerabilities highlighted by the 
neglected disease advocates. A cost effectiveness analysis of these investments could 
technically provide an indication of what a dollar could purchase per intervention type. 
However the success of programmes still tends to be measured often by their coverage 
rather than by longer term outcomes, and in global health, seldom by improvements in the 
levels of poverty and broader development. Reasons for this include the time limited nature 
of programmes; the discipline focus of people involved in programmes, that is health sector 
and therefore the disease focus – lack of capacity to design the relevant research, monitoring 
and evaluation tools that would allow a focus that were any broader.  
To focus on the addressing neglect and vulnerabilities from a health perspective would 
require a different way of conceptualising the link between poverty, health and disease, 
acknowledging the complexities and developing appropriate and realistic solutions. This 
would mean more than a simple combination of individual supplementary (vertical) 
programmes. It would also necessarily require a redefinition of outcomes and successes, 
working to a longer time frame than is currently adhered to in disease based vertical 
programmes. A detailed discussion is beyond the scope of this paper.  
6. Conclusion 
Diseases of poverty represent a rich and dynamic interplay between the context of people’s 
lives and the disease process. The interaction is complex and evolves within a social and 
cultural context as much as it does within a physical and biological context. Understanding 
this complex dynamic is crucial for the sustainable management of diseases of poverty. The 
evidence from the health literature, however, is that there is little investigator driven social 
science research to speak of in the diseases of poverty, and a similarly poor presence of 
interdisciplinary science. Without this, our understanding and management of diseases of 
poverty is inevitably reduced to a strategy that relies on a repetitive, reductionist flat-world 
science to overcome an acknowledged complex system. 
The research to address neglected diseases of poverty needs more sophisticated funders and 
priority setters. Pharmaceuticals (including vaccines) are critical, but they are not the only 
solutions, and their final application is not in flat worlds. Their application is in complex 
dynamic worlds in which pathologies evolve to exploits the social nature of humans. Our 
current understanding of the dynamic, and our understanding of how to develop 
sustainable approaches to disease management are poor. There are no research templates to 
overcome this, and the silos of current science into the diseases of poverty have discouraged 
the development of genuinely interdisciplinary research. 
As a major recommendation there is a need to reconceptualise the outcomes for addressing 
vulnerability and the addressing the health needs of the neglected, poor, disenfranchised 
and dispossessed. Recognising that the challenges cannot be reduced to simplistic 
biomedical solutions is a first step. Global public health is ideally placed to bring together 
the different disciplines to engage in these developments.  
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